Alendronate reduces osteoclast precursors in osteoporosis

Osteoporosis International

Volumn 21, Issue 10, 2010, Pages 1741-1750

  D'Amelio, P ^a   Grimaldi, A ^a   Cristofaro, M A ^a   Ravazzoli, M ^a   Molinatti, P A ^a   Pescarmona, G P ^a,b   Isaia, G C ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

Author keywords

Alendronate; Osteoclast; Osteoclast precursors; Osteoporosis; RANKL

Indexed keywords

ALENDRONIC ACID; ALENDRONIC ACID PLUS COLECALCIFEROL; CACIT VITD3; CALCIUM PLUS COLECALCIFEROL; COLECALCIFEROL; CYTOKINE; OSTEOCLAST DIFFERENTIATION FACTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CELL CULTURE; CELL VIABILITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PARAMETER; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEM CELL; TREATMENT OUTCOME;

AGED; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; CALCIUM; CELLS, CULTURED; CYTOKINES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MIDDLE AGED; OSTEOCLASTS; OSTEOPOROSIS, POSTMENOPAUSAL; RANK LIGAND; STEM CELLS; VITAMIN D;

EID: 77956414685     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-009-1129-1     Document Type: Article

References (48)

1. MJ Rogers 2003 New insights into the molecular mechanisms of action of bisphosphonates Curr Pharm Des 9 2643 2658 1:CAS:528:DC%2BD3sXpsVCkt7Y%3D 10.2174/1381612033453640 14529538
2. HL Benford NW McGowan MH Helfrich ME Nuttall MJ Rogers 2001 Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro Bone 28 465 473 1:CAS:528:DC%2BD3MXjtlChsL4%3D 10.1016/S8756-3282(01)00412-4 11344045
3. H Sudhoff JY Jung J Ebmeyer BT Faddis H Hildmann RA Chole 2003 Zoledronic acid inhibits osteoclastogenesis in vitro and in a mouse model of inflammatory osteolysis Ann Otol Rhinol Laryngol 112 780 786 14535562
4. MJ Rogers KM Chilton FP Coxon J Lawry MO Smith S Suri RG Russell 1996 Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide-independent mechanism J Bone Miner Res 11 1482 1491 1:CAS:528:DyaK28XmsValtb8%3D 10.1002/jbmr.5650111015 8889848
5. DE Hughes KR Wright HL Uy A Sasaki T Yoneda GD Roodman GR Mundy BF Boyce 1995 Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo J Bone Miner Res 10 1478 1487 1:CAS:528:DyaK2MXpsFGmsbo%3D 10.1002/jbmr.5650101008 8686503
6. MG Cecchini R Felix H Fleisch PH Cooper 1987 Effect of bisphosphonates on proliferation and viability of mouse bone marrow-derived macrophages J Bone Miner Res 2 135 142 1:CAS:528:DyaL2sXkvV2rtrc%3D 10.1002/jbmr.5650020209 3455162
7. PM Boonekamp LJ van der Wee-Pals MM van Wijk-van Lennep CW Thesing OL Bijvoet 1986 Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix Bone Miner 1 27 39 1:CAS:528:DyaL28XktVSmurc%3D 3508715
8. GA Rodan AA Reszka 2002 Bisphosphonate mechanism of action Curr Mol Med 2 571 577 1:CAS:528:DC%2BD38XmvFOhtrg%3D 10.2174/1566524023362104 12243249
9. S Colucci V Minielli G Zambonin N Cirulli G Mori M Serra V Patella A Zambonin Zallone M Grano 1998 Alendronate reduces adhesion of human osteoclast-like cells to bone and bone protein-coated surfaces Calcif Tissue Int 63 230 235 1:CAS:528:DyaK1cXlvFWrt7s%3D 10.1007/s002239900519 9701627
10. A Carano SL Teitelbaum JD Konsek PH Schlesinger HC Blair 1990 Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro J Clin Invest 85 456 461 1:CAS:528:DyaK3cXhsFWmtbs%3D 10.1172/JCI114459 2105340
11. M Sato W Grasser N Endo R Akins H Simmons DD Thompson E Golub GA Rodan 1991 Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure J Clin Invest 88 2095 2105 1:CAS:528: DyaK38XjsVGgtA%3D%3D 10.1172/JCI115539 1661297
12. P D'Amelio A Grimaldi S Di Bella C Tamone SZ Brianza MG Ravazzoli P Bernabei MA Cristofaro GP Pescarmona G Isaia 2008 Risedronate reduces osteoclast precursors and cytokine production in postmenopausal osteoporotic women J Bone Miner Res 23 373 379 10.1359/jbmr.071031 17967134
13. H Dobnig LC Hofbauer V Viereck B Obermayer-Pietsch A Fahrleitner-Pammer 2006 Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients Osteoporos Int 17 693 703 1:CAS:528:DC%2BD28XjsVertrw%3D 10.1007/s00198-005- 0035-4 16435076
14. A Sauty M Pecherstorfer I Zimmer-Roth P Fioroni L Juillerat M Markert H Ludwig P Leuenberger P Burckhardt D Thiebaud 1996 Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy Bone 18 133 139 1:STN:280:DyaK28vjtVSmtQ%3D%3D 10.1016/8756-3282(95)00448-3 8833207
15. RE Hewitt A Lissina AE Green ES Slay DA Price AK Sewell 2005 The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins Clin Exp Immunol 139 101 111 1:CAS:528:DC%2BD2MXhtFWmtr0%3D 10.1111/j.1365-2249.2005.02665.x 15606619
16. K Thompson MJ Rogers 2004 Statins prevent bisphosphonate-induced gamma, delta-T-cell proliferation and activation in vitro J Bone Miner Res 19 278 288 1:CAS:528:DC%2BD2cXhs1elsr0%3D 10.1359/JBMR.0301230 14969398
17. G Mossetti D Rendina G De Filippo R Viceconti G Di Domenico M Cioffi L Postiglione V Nunziata 2005 Interleukin-6 and osteoprotegerin systems in Paget's disease of bone: relationship to risedronate treatment Bone 36 549 554 1:CAS:528:DC%2BD2MXisFGrtLs%3D 10.1016/j.bone.2004.11.004 15777635
18. HA Papadaki C Tsatsanis A Christoforidou N Malliaraki M Psyllaki C Pontikoglou M Miliaki AN Margioris GD Eliopoulos 2004 Alendronate reduces serum TNFalpha and IL-1beta, increases neutrophil counts, and improves bone mineral density and bone metabolism indices in patients with chronic idiopathic neutropenia (CIN)-associated osteopenia/osteoporosis J Bone Miner Metab 22 577 587 1:CAS:528:DC%2BD2cXosVSlu7Y%3D 10.1007/s00774-004-0526-y 15490268
19. D Santini ME Fratto B Vincenzi A La Cesa C Dianzani G Tonini 2004 Bisphosphonate effects in cancer and inflammatory diseases: in vitro and in vivo modulation of cytokine activities BioDrugs 18 269 278 1:CAS:528: DC%2BD2cXntlWitb8%3D 10.2165/00063030-200418040-00004 15244502
20. A Gur A Denli R Cevik K Nas M Karakoc AJ Sarac 2003 The effects of alendronate and calcitonin on cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study Yonsei Med J 44 99 109 1:CAS:528:DC%2BD3sXislKnsLo%3D 12619182
21. M Sahni HL Guenther H Fleisch P Collin TJ Martin 1993 Bisphosphonates act on rat bone resorption through the mediation of osteoblasts J Clin Invest 91 2004 2011 1:CAS:528:DyaK3sXktVSqs70%3D 10.1172/JCI116422 8486770
22. C Vitte H Fleisch HL Guenther 1996 Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption Endocrinology 137 2324 2333 1:CAS:528:DyaK28XjtFWrt7c%3D 10.1210/en.137.6.2324 8641182
23. JA Kanis 1994 Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group Osteoporos Int 4 368 381 1:STN:280:DyaK2M3htVyktA%3D%3D 10.1007/BF01622200 7696835
24. P D'Amelio A Grimaldi GP Pescarmona C Tamone I Roato G Isaia 2005 Spontaneous osteoclast formation from peripheral blood mononuclear cells in postmenopausal osteoporosis Faseb J 19 410 412 15611151
25. CT Ritchlin SA Haas-Smith P Li DG Hicks EM Schwarz 2003 Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis J Clin Invest 111 821 831 1:CAS:528:DC%2BD3sXitlOjsbc%3D 12639988
26. N Dalbeth T Smith B Nicolson B Clark K Callon D Naot DO Haskard FM McQueen IR Reid J Cornish 2008 Enhanced osteoclastogenesis in patients with tophaceous gout: urate crystals promote osteoclast development through interactions with stromal cells Arthritis Rheum 58 1854 1865 1:CAS:528:DC%2BD1cXotVOntL8%3D 10.1002/art.23488 18512794
27. M Ramnaraine W Pan DR Clohisy 2006 Osteoclasts direct bystander killing of cancer cells in vitro Bone 38 4 12 1:CAS:528:DC%2BD28Xks1Sg 10.1016/j.bone.2005.07.016 16139579
28. HM Massey AM Flanagan 1999 Human osteoclasts derive from CD14-positive monocytes Br J Haematol 106 167 170 1:STN:280:DyaK1MzntlGltw%3D%3D 10.1046/j.1365-2141.1999.01491.x 10444181
29. V Shalhoub G Elliott L Chiu R Manoukian M Kelley N Hawkins E Davy G Shimamoto J Beck SA Kaufman G Van S Scully M Qi M Grisanti C Dunstan WJ Boyle DL Lacey 2000 Characterization of osteoclast precursors in human blood Br J Haematol 111 501 512 1:STN:280:DC%2BD3M7hs1KjsA%3D%3D 10.1046/j.1365-2141.2000. 02379.x 11122091
30. J Faust DL Lacey P Hunt TL Burgess S Scully G Van A Eli Y Qian V Shalhoub 1999 Osteoclast markers accumulate on cells developing from human peripheral blood mononuclear precursors J Cell Biochem 72 67 80 1:CAS:528: DyaK1cXnvVegsrw%3D 10.1002/(SICI)1097-4644(19990101)72:1<67::AID-JCB8>3.0. CO;2-A 10025668
31. A Matayoshi C Brown JF DiPersio J Haug Y Abu-Amer H Liapis R Kuestner R Pacifici 1996 Human blood-mobilized hematopoietic precursors differentiate into osteoclasts in the absence of stromal cells Proc Natl Acad Sci USA 93 10785 10790 1:CAS:528:DyaK28XmtVOltb0%3D 10.1073/pnas.93.20.10785 8855258
32. I Roato M Grano G Brunetti S Colucci A Mussa O Bertetto R Ferracini 2005 Mechanisms of spontaneous osteoclastogenesis in cancer with bone involvement Faseb J 19 228 230 1:CAS:528:DC%2BD2MXhtFehsr0%3D 15550550
33. ER van Beek CW Lowik SE Papapoulos 1997 Effect of alendronate treatment on the osteoclastogenic potential of bone marrow cells in mice Bone 20 335 340 10.1016/S8756-3282(97)00006-9 9108353
34. ER Van Beek CW Lowik SE Papapoulos 2002 Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors Bone 30 64 70 10.1016/S8756-3282(01)00655-X 11792566
35. FP Coxon K Thompson AJ Roelofs FH Ebetino MJ Rogers 2008 Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells Bone 42 848 860 1:CAS:528:DC%2BD1cXkvVOqsbg%3D 10.1016/j.bone.2007.12.225 18325866
36. P D'Amelio A Grimaldi S Di Bella SZ Brianza MA Cristofaro C Tamone G Giribaldi D Ulliers GP Pescarmona G Isaia 2008 Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: a key mechanism in osteoporosis Bone 43 92 100 10.1016/j.bone.2008.02.017 18407820
37. G Brunetti S Colucci P Pignataro M Coricciati G Mori N Cirulli A Zallone FR Grassi M Grano 2005 T cells support osteoclastogenesis in an in vitro model derived from human periodontitis patients J Periodontol 76 1675 1680 1:CAS:528:DC%2BD2MXhtF2ntr3P 10.1902/jop.2005.76.10.1675 16253089
38. BJ Olivier T Schoenmaker RE Mebius V Everts CJ Mulder KM van Nieuwkerk TJ de Vries SW van der Merwe 2008 Increased osteoclast formation and activity by peripheral blood mononuclear cells in chronic liver disease patients with osteopenia Hepatology 47 259 267 1:CAS:528:DC%2BD1cXhtlChsb0%3D 10.1002/hep.21971 18022900
39. ST Tjoa TJ de Vries T Schoenmaker A Kelder BG Loos V Everts 2008 Formation of osteoclast-like cells from peripheral blood of periodontitis patients occurs without supplementation of macrophage colony-stimulating factor J Clin Periodontol 35 568 575 1:CAS:528:DC%2BD1cXovFeltr0%3D 10.1111/j.1600-051X.2008.01241.x 18435789
40. LC Hofbauer CA Kuhne V Viereck 2004 The OPG/RANKL/RANK system in metabolic bone diseases JMNI 4 268 275 1:CAS:528:DC%2BD2cXhtVGmtbrJ 15615494
41. I Roato G Brunetti E Gorassini M Grano S Colucci L Bonello L Buffoni R Manfredi E Ruffini D Ottaviani L Ciuffreda A Mussa R Ferracini 2006 IL-7 up-regulates TNF-alpha-dependent osteoclastogenesis in patients affected by solid tumor PLoS ONE 1 e124 10.1371/journal.pone.0000124 17205128
42. De Vries TJ, Everts V (2009) Osteoclast formation from peripheral blood of patients with bone-lytic diseases
43. X Deng Z Yu H Funayama K Yamaguchi T Sasano S Sugawara Y Endo 2007 Histidine decarboxylase-stimulating and inflammatory effects of alendronate in mice: involvement of mevalonate pathway, TNFalpha, macrophages, and T-cells Int Immunopharm 7 152 161 1:CAS:528:DC%2BD28XhtlaltL7O 10.1016/j.intimp.2006.09.009
44. P Pietschmann P Stohlawetz S Brosch G Steiner JS Smolen M Peterlik 1998 The effect of alendronate on cytokine production, adhesion molecule expression, and transendothelial migration of human peripheral blood mononuclear cells Calcif Tissue Int 63 325 330 1:CAS:528:DyaK1cXmsVehurg%3D 10.1007/s002239900535 9744992
45. A Toyras J Ollikainen M Taskinen J Monkkonen 2003 Inhibition of mevalonate pathway is involved in alendronate-induced cell growth inhibition, but not in cytokine secretion from macrophages in vitro Eur J Pharm Sci 19 223 230 1:CAS:528:DC%2BD3sXls1Omsr8%3D 10.1016/S0928-0987(03)00108-8 12885386
46. B Pan AN Farrugia LB To DM Findlay J Green K Lynch AC Zannettino 2004 The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE) J Bone Miner Res 19 147 154 1:CAS:528:DC%2BD2cXnt1Kgug%3D%3D 10.1359/jbmr.2004.19.1.147 14753746
47. RG Russell NB Watts FH Ebetino MJ Rogers 2008 Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy Osteoporos Int 19 733 759 1:CAS:528:DC%2BD1cXltFyjurw%3D 10.1007/s00198-007-0540-8 18214569
48. RG Russell Z Xia JE Dunford U Oppermann A Kwaasi PA Hulley KL Kavanagh JT Triffitt MW Lundy RJ Phipps BL Barnett FP Coxon MJ Rogers NB Watts FH Ebetino 2007 Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy Ann N Y Acad Sci 1117 209 257 1:CAS:528:DC%2BD1cXhtVGmurY%3D 10.1196/annals.1402.089 18056045